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ABSTRACT
Chronic kidney disease (CKD) is associated with high healthcare costs, poor health outcomes
and low quality of life (Donald et al., 2018). The US CKD prevalence is 15%, costing Medicare
$79 billion in 2016 (United States Renal Data System, 2018). Self-management could reduce
CKD burden (Jeddi, Nabovati, and Amirazodi, 2017). Mobile technology offers a low-cost, easeof-access platform for chronic disease self-management (Whitehead & Seaton, 2016),
potentially slowing disease progression and improving health outcomes (Jeddi, 2017). The
purpose of this project was to utilize a CKD-specific mobile application, CARELogiQ, to facilitate
symptom management; increasing patient satisfaction and decreasing hospitalizations and ER
visits over three months. A five-database literature review yielded six high-quality articles; three
level I, two level II, and one level III evidence based on JHNEBP (Dang & Dearholt, 2017).
Evidence supports a multifaceted approach to effectively use a CKD-specific mobile application
for patient and provider communications, appointment and biometric check reminders,
education, and telemonitoring of BP and weight. The Stetler Model guided the project (Stetler,
2001). In a Northwest Indiana nephrology clinic, CARELogiQ was used to report symptoms,
communicate with patients and providers, and record medical appointments. DaVita’s Kidney
Smart© educational class provided education. Participants recorded weekly BP and weights
manually in a log. Weekly calls collected BP and weight results, reminded participants to use
CARELogiQ to report symptoms, encouraged medication adherence, and continued
telemonitoring. Aggregate and person-to-person hospitalization/ER visit comparisons, and a
post-intervention satisfaction-of-care survey were completed. Healthcare utilization was less in
the intervention group (N = 10, M = 0.00, SD = 0.00) compared to the non-intervention group (N
= 32, M = 0.125, SD = 0.42) (t(40) = .930, p = .36) . Rate of healthcare utilization in the
intervention group (N = 10) did not change from pre (M = 0.00, SD = 0.00) to post-intervention
(M = 0.00, SD = 0.00). Participants were satisfied with use of CARELogiQ. CARELogiQ has the
potential to reduce healthcare utilization by improving self-management, thus effectively

MOBILE APPLICATION IN CKD POPULATION

ix

impacting CKD burden. Significant outcomes may be attainable for future CARELogiQ projects
by increasing sample size, lengthening implementation time, increasing functionality of
CARELogiQ, and providing a smart device to participants.
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CHAPTER 1
INTRODUCTION
Background
Chronic kidney disease (CKD) is defined by the Kidney Disease Improving Global Outcomes
(KDIGO) as any consequential kidney structure or function abnormalities persisting greater than
three months (2012). Hypertension (HTN) and diabetes mellitus (DM) are the most common
causes of CKD (NKF, 2017). Based on the National Kidney Foundation’s (NKF) Kidney Disease
Outcomes Quality Initiative (KDOQI) 2002 guidelines, moderate CKD or Stage 3 CKD is
described by a glomerular filtration rate (GFR) of 30 to 59 mL/min/1.73 m2, and severe CKD,
Stage 4, is a GFR of 15-29 mL/min/1.73 m2 (KDOQI, 2002). The 2012 KDIGO guidelines further
subcategorize the stages of CKD with albuminuria categories a1, a2, and a3 (KDIGO, 2012).
While many patients do not experience symptoms until irreversible kidney damage has
occurred, patients with CKD may experience nausea and vomiting, lack of appetite, fatigue and
weakness, difficulty sleeping and mental impairments, muscle cramps, lower extremity swelling,
itching, chest pain and shortness of breath, and changes in urination (Mayo Foundation for
Medical Education and Research, 2018).
In the United States (US), the prevalence of CKD Stages 1-5 is 15%, with CKD Stages 3-5
at 7%, costing Medicare $79 billion for all CKD beneficiaries in 2016 (United States Renal Data
System (USRDS, 2018). These numbers do not take into account the costs of CKD progressing
into dialysis or kidney transplant. CKD is associated with high healthcare costs, as well as
adversely affecting health outcomes and quality of life (Donald et al., 2018). Control of HTN and
DM, along with correction of metabolic acidosis are part of the interventions identified to reduce
progression of the disease (Vassalotti, Centor, Turner, Greer, Choi, Sequist, & NKF KDOQI,
2015). Symptom management would decrease hospitalization and emergency room (ER) visits,
thus decreasing utilization of healthcare (He et al., 2017).
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Data from the Literature Supporting Need for the Project
Vassalotti et al. (2015) encouraged the majority of CKD patients to be cared for by primary
care clinicians, due to the prevalence of CKD exceeding the availability of nephrologists. Other
literature suggests that self-management of CKD could also decrease the burden of this patient
population on the healthcare system (Jeddi, Nabovati, & Amirazodi, 2017). According to
Whitehead and Seaton (2016), chronic disease health outcomes may improve with selfmanagement programs. The Institute of Medicine defines self-management as the individual’s
responsibilities to live well with one or more chronic diseases, which is commonly used in the
literature pertaining to self-management topics (Packer, Francini, Audulv, Alizadeh, van Gaal,
Warner, & Kephart, 2018). Lee, Wu, Hsieh, and Tsai (2016) further echo this definition of selfmanagement, adding that self-management encompasses self-monitoring and symptom
management.
Mobile technology (mHealth) may offer a low cost, ease of access platform to implement
self-management interventions of chronic conditions (Whitehead & Seaton, 2016). In recent
years, healthcare has seen a boom of mobile phone applications (app) utilized not only for
chronic disease management, but specifically CKD as well, including self-management (Jeddi et
al., 2017). Utilizing an app to self-manage CKD along with symptom monitoring has the potential
to slow disease progression and improve health outcomes (Jeddi et al., 2017). While poor selfmanagement and lack of adherence to treatment guidelines can lead to adverse clinical
outcomes, this type of app can facilitate the patient’s self-management by easing the acquisition
of health information and improving communication with HCPs, as well as encouraging
compliance with blood sugar and blood pressure (BP) monitoring, supporting physical activity,
providing nutritional guidelines, and promoting adherence to medication regimens (Jeddi et al.,
2017).
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Data from the Clinical Agency Supporting Need for the Project
A local nephrologist has developed an app to facilitate CKD self-management in his patient
population. The app has the ability to record and, if necessary, access the patient’s health care
provider (HCP) to report symptoms, as well as deliver personalized education to the patient.
The nephrologist was interested in utilizing the app for symptom management with a goal to
increase patient satisfaction of their care with the use of the app, while decreasing healthcare
utilization, including hospitalizations and ER visits. Out of 264 active patients, the practice had
180 patients with stage III to stage V CKD.
Purpose of the Evidence-Based Practice Project
The purpose of this project was to evaluate the effectiveness of a mobile application
developed by a local nephrologist to facilitate symptom management in order to increase patient
satisfaction and to decrease hospitalizations and emergency room visits over a four-month
period.
PICOT Question
Among patients with moderate to severe CKD (P), how effective is the mobile application,
CARELogiQ, to self-manage symptoms (I) compared to non-intervention (C) in order to reduce
healthcare utilization and increase patient satisfaction with care (O) over a four-month period
(T).
Significance of the EBP Project
Implications of this project were to initiate the use of an app developed by a local
nephrologist in an outpatient CKD clinic to positively affect CKD self-management resulting in
increased patient satisfaction of care and decreased hospitalizations and ER visits. Selfmanagement in this CKD population has the potential to improve healthcare outcomes, as well
as decrease costs associated with hospitalization and ER visits.
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CHAPTER 2
EBP MODEL AND REVIEW OF LITERATURE
In this chapter, the process of this EBP project will be expanded upon with the guidance
of the Stetler model of evidenced-based practice. “Johns Hopkins Nursing Evidence-Based
Practice Research Evidence Appraisal Tool” (JHNEBP) is utilized to appraise the level and
quality of evidence used to develop best practice recommendations in order to guide the
practice change.
Evidence-based Practice Model
Overview of EBP Model
The Stetler model of evidenced-based practice is a step-by-step approach to use
research evidence in developing nursing practice (Stetler, 2001). Research can be used
instrumentally, conceptually, or symbolically, in an informal or formal way, directly or indirectly,
at the level of the individual, group, or organization (Schmidt & Brown, 2019). According to
Stetler (2001), the use of knowledge is influenced not only by a user’s internal characteristics,
but also by external environmental factors. This model consists of five phases: Preparation,
Validation, Comparative Evaluation/Decision Making, Translation/Application, and Evaluation
(Stetler, 2001). The model was selected to guide this project due to the applicability to an
individual practitioner with an increased level of knowledge and skill, which facilitated decision
making to translate research findings into practice (Stetler, 2001). This model guided the
process of participants using a mobile application to self-manage symptoms associated with
CKD.
Application of EBP Model to DNP Project
Phase I: Preparation. The first step in the Stetler model is identifying the problem. The
problem for this EBP project is CKD being associated with high healthcare costs, as well as
adversely affecting health outcomes and quality of life (Donald et al., 2018). The catalyst for this
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specific project was an innovative program goal. A local nephrologist developed a mobile app
and requested a project leader to guide operationalizing this intervention. The interest of the
nephrologist in launching a newly developed app is an influencing factor. The project leader
seeks to know if employment of a mobile application to manage symptoms decreases
unscheduled healthcare utilization. The literature was reviewed based on a clinical question and
a PICOT question was developed. A search strategy was prepared as shown in Table 2.1. The
highest levels of evidence were sought to guide this project.
Phase II: Validation. The second step in the Stetler model is validation (Stetler, 2001).
The literature was searched for relevant articles pertaining to the use of a mobile app to
promote self-management of chronic diseases, including CKD. The selected articles were
evaluated and appraised with the JHNEBP tool for level and quality. An evidence table was
created, as shown in Table 2.2, including the level and quality of each piece of evidence. The
project leader decided to continue the EBP process due to the selected evidence determined to
be fit for use.
Phase III: Comparative evaluation/Decision Making. In the comparative evaluation
and decision-making phase, synthesis of the evidence and evaluation of commonalities to be
used in project was completed, leading to best practice recommendations. The project leader
decided to use these findings to change practice by using the CARELogiQ app to aid
participants in self-management of CKD.
Phase IV: Translation/Application. A plan of change to implement the CARELogiQ
app was formulated and was acted upon. Participants downloaded the mobile app and utilized
the platform as previously described.
Phase V: Evaluation. In this phase, the project leader evaluated the outcome data to
determine if the practice change of implementing the CARELogiQ app to facilitate symptom
management met the outcome goals of increasing patient satisfaction and reducing healthcare
utilization over a four-month period. Formal evaluation (formative and summative) of the
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implementation of a mobile app to manage symptoms to decrease unscheduled healthcare
utilization was conducted in this stage.
Strengths and Limitations of EBP Model for DNP Project
Strengths of the Stetler model include the ability to integrate research into practice either
informally or formally, at an individual level or up to an organizational level, incorporating
evidence into daily practice. Since the project leader was working mostly on her own, this model
worked to guide the EBP project. The model also accommodated for collaboration with staff
during retrieval of patient information.
A limitation of the Stetler model is the need for a project leader to be competent, having
sufficient knowledge and skill of EBP practice to successfully use this EBP model.
Literature Search
Sources Examined for Relevant Evidence
An exhaustive search of the following databases was completed (see Table 2.1):
Cumulative Index of Nursing and Allied Health Literature (CINAHL), Cochrane Library, Johana
Briggs Institute (JBI), Medline with full text via EBSCO (Medline), ProQuest Nursing and Allied
Health Literature (ProQuest). Keywords searched within CINAHL, Medline, and ProQuest with
Boolean operators were (“chronic kidney disease*” OR “chronic disease*”) AND (mHealth OR
m-health OR “mobile app*” OR “mobile health” OR smartphone* OR “cell* phone*”) AND (“self
manag*” OR “self care”). Cochrane Library was searched with the MeSH heading (MM mobile
applications). JBI was searched with (chronic kidney disease OR chronic disease AND mHealth
OR m-health OR mobile application OR mobile health OR smartphone OR cellphone) with a
five-year limiter. While CKD was the focus of this EBP project, due to the limited results specific
to CKD, the search was expanded to chronic diseases as well. A Prisma flow diagram (see
Figure 2.1) details the search process.
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Table 2.1
Literature Search Results
Database
CINHAL

Keyword(s)
(“chronic kidney
disease*” OR
“chronic disease*”)
AND (mHealth OR

Limiters
English
Peer
Reviewed

Date
Restraints
June 2014June 2019

Results

Relevance/Saved

74

2 Systematic
Reviews

m-health OR “mobile
app*” OR “mobile
health” OR
smartphone* OR
“cell* phone*”) AND
(“self manag*” OR
“self care”)

Cochrane
Library

(MM mobile
applications)

English
Peer
Reviewed

June 2014June 2019

4

0

Johana
Briggs
Institute

(“chronic kidney
disease*” OR
“chronic disease*”)
AND (mHealth OR

English
Peer
Reviewed

June 2014June 2019

25

0

English
Peer
Reviewed

June 2014June 2019

252

3 (2 Systematic
Reviews, 1
Overview of
Systematic
Reviews, 2
duplicates from
CINAHL)

English

June 2014June 2019

541

0 (2 duplicates in
Medline)

m-health OR “mobile
app*” OR “mobile
health”)

Medline
with Full
text via
EBSCO

(“chronic kidney
disease*” OR
“chronic disease*”)
AND (mHealth OR
m-health OR “mobile
app*” OR “mobile
health” OR
smartphone* OR
“cell* phone*”) AND
(“self manag*” OR
“self care”)

ProQuest
Nursing and
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Health
Database

(“chronic kidney
disease*” OR
“chronic disease*”)
AND (mHealth OR

9

Peer
Reviewed

m-health OR “mobile
app*” OR “mobile
health” OR
smartphone* OR
“cell* phone*”) AND
(“self manag*” OR
“self care”)

Hand
Search
(JMIR
2018)

English
Peer
Reviewed

June 2014June 2019

1 Systematic
Review of
Systematic
Reviews
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Figure 2.1

Included

Eligibility

Screening

Identification

Prisma Flow Diagram

Records identified through
database searching (n = 897)
Duplicates excluded
(n = 4)
Records after duplicates
removed (n = 893)

Records screened
(n = 893)
Records excluded
(n = 864)
Full text articles
assessed for
eligibility (n = 29)
Full-text articles excluded
based on
inclusion/exclusion criteria
(n = 23)

Studies included for
synthesis (n = 6)

MOBILE APPLICATION IN CKD POPULATION

11

Levels of Evidence
Level of evidence for this EBP project was assessed by using the JHNEBP, which
categorizes evidence based on the level of study design (Dang & Dearholt, 2017). Dang and
Dearholt (2017) presume that the higher the level and quality of the evidence, the stronger the
recommendation represents best practice. Answering three simple questions determines the
level of evidence, ranging from I to III (Dang & Dearholt, 2017).
Level I evidence incorporates the following study types: experimental studies,
randomized controlled trials (RCTs), explanatory mixed methods with only level I quantitative
studies, or systematic reviews of RCTs, with or without meta-analysis (Dang & Dearholt, 2017).
Dang and Dearholt (2017) categorize level II evidence as quasi-experimental studies,
explanatory mixed methods with only level II quantitative studies, or systematic reviews
consisting of RCTs and/or quasi-experimental studies, with or without meta-analysis. Level III
evidence is comprised of quantitative nonexperimental studies; explanatory mixed methods with
only level III quantitative studies; exploratory, convergent, or multiphasic mixed methods
studies; systematic reviews of a combination of RCTs, quasi-experimental, and/or
nonexperimental studies; or qualitative studies or systematic reviews of qualitative studies, with
or without meta-analysis (Dang & Dearholt, 2017).
The evidence used in this EBP project were all systematic reviews ranging from level I
(three pieces of evidence utilizing all RCTs) to level II (three pieces of evidence utilizing a
combination of RCTs and non-RCTs) (see Table 2.2).
Appraisal of Relevant Evidence
JHNEBP also facilitates appraisal of quality of evidence by utilizing a straightforward 12item checklist to appraise the quality of systematic reviews, ranging from High to Low (Dang &
Dearholt, 2017). High quality evidence is consistent with generalizable results; sufficient sample
sizes for study design; and provides adequate control, definite conclusions, and consistent
recommendations which is based on a comprehensive, scientific literature review (Dang &
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Dearholt, 2017). Good quality differs from high quality in that results are reasonably consistent,
with some control; conclusions are fairly definitive; and recommendations are reasonably
consistent, based on fairly comprehensive literature that includes some scientific evidence
(Dang & Dearholt, 2017). Grades of Low quality or Major flaw encompass little evidence with
inconsistent results, insufficient sample size for the study design, and inability to draw
conclusions (Dang & Dearholt, 2017). All six of the systematic reviews used in this EBP project
were of high quality, based on JHNEBP, although many of the studies used in the reviews were
of moderate to low quality, due to small sample sizes.
Level I evidence. Jeddi et al. (2017) produced a systematic review of eight RCTs
evaluating the efficacy of IT-based interventions on self-management clinical outcomes (BP,
interdialytic weight gain, intact parathyroid hormone, and ultrafiltration rate) and process of care
outcomes (medication adherence, patient knowledge, medication dose/usage, BP, and sodium
intake) in CKD patients. The interventional classifications consisted of use of
smartphone/personal digital assistant devices (PDAs) (software/application/short message
service (SMS)) to transfer data to HCP/researchers, use of wearable devices to record BP and
weight, computerized systems for data transfer to and from patients through the internet, or a
combination of all three. The duration of the studies lasted from three weeks to 12 months. The
smartphone/PDA functionalities were categorized by inform, record, display, communicate,
remind/alert, and guide. The results showed statistically significant outcomes in 80% of the
studies, with 75% being clinical outcomes and 86% process of care outcomes. Quality was
assessed as high, based on the results (consistent, generalizable), sample size (sufficient),
control (adequate), conclusions (definite), and recommendations (consistent/based on scientific
evidence).
Lee, Choi, Lee, and Jiang (2018) completed a systematic review of 12 RCTs to examine
the effectiveness of mHealth interventions on chronic disease management health outcomes
and process measures. MHealth interventions utilized smartphones as a mobile device, tablets,
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or telemonitoring wireless devices with components of remote symptom monitoring/selfassessment, automatic messages, and education. Duration of studies ranged from two to 12
months. Health outcomes were measurements of physical functioning (gait/balance, fatigue,
etc.), psychological functioning (quality of life, depression, and anxiety), medication adherence,
and/or ease of symptom evaluation and reporting to HCPs. Process measures included patient
satisfaction and interventional feasibility. Incorporating mobile applications in chronic disease
management showed a statistically significant effect on outcomes of interest in 83.3% of the
studies. The authors concluded that automated text reminders, frequent and accurate symptom
monitoring, and improved communication between patients and HCPs result in improved
chronic condition self-management. Quality was assessed as high, based on the results
(consistent, generalizable), sample size (sufficient), control (adequate), conclusions (definite),
and recommendations (consistent/based on scientific evidence).
Whitehead and Seaton (2016) conducted a systematic review of nine RCTs assessing
the efficacy of symptom self-management utilizing mobile phone and tablet apps on disease
specific outcomes, which included blood glucose (BG), asthma symptoms, medication use,
peak flows, BP, weight, and pedometer counts. Interventions included the use of a disease
specific app with or without automatic feedback, either alone or in combination with clinician
input or support (either by text or phone call). Chronic diseases of patients in this study included
DM, chronic lung disease, and cardiovascular disease (CVD). The duration or ranged from three
months to one year. Statistically significant effects were shown in 66.6% of studies on disease
specific outcomes and some combination of app usage. App only interventions were statistically
significant in improvement of symptom management in 60% of the studies. Quality was
assessed as high, based on the results (consistent, generalizable), sample size (sufficient),
control (adequate), conclusions (definite), and recommendations (consistent/based on scientific
evidence).
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Level II evidence. A systematic review of systematic reviews by Kitsiou, Pare, Jaana,
and Gerber (2017) evaluated the efficacy of mHealth interventions of remote patient monitoring
and clinical feedback delivery for DM self-management (encouragement, education, reminders,
and recommendations) on glycemic control in diabetic patients. This review examined 15
systematic reviews, seven of which were comprised of RCTs only and the remaining were
comprised of RCTs, non-RCTs, and cohort studies with pre-post design. MHealth interventions
included SMS, mobile applications, Blue-tooth enabled glucometers, and data entry/patient
support through cellphone accessible websites/web-portals. Duration of studies were from two
weeks to 12 months, with most study durations being three to 12 months. The one measurable
outcome was glycemic control defined by HgA1c. There was no effect found from text
messaging alone. Nonstatistical positive effect was found with combination of SMS and internet
app for transmission of BG, reinforcement of diet/exercise, education and medication
adjustment. Text messaging combined with clinical feedback had a statically significant effect on
glycemic control. Addition of an education component increased the effect size. Quality was
assessed as high, based on the results (consistent, generalizable), sample size (sufficient),
control (adequate), conclusions (definite), and recommendations (consistent/based on scientific
evidence).
A systematic review of 23 systematic reviews of RCTs and non-RCTs by Marcolino et al.
(2018) evaluated the effects of mHealth interventions on chronic and noncommunicable
diseases, such as asthma, cardiac disease, congestive heart failure, chronic lung disease,
cancer, and DM. The most frequent interventions included SMS for reminders, education,
motivation, or prevention. Duration of interventions lasted from a few minutes to 24 months.
Primary outcomes were divided into clinical outcomes (frequency of hypoglycemic events,
symptoms, or death), surrogate outcomes (HgA1c, BP, lipid profile, CVD risk profile, lung
function, neb use, weight, BMI, behavioral or lifestyle changes), and process of care outcomes
(attendance rates, medication compliance, data management, communication, time to dx, time
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to treat, or professional workload changes). Secondary outcomes were cost, patient satisfaction,
and potential harms and adverse effects. Regarding clinical outcomes, mHealth interventions
improved symptoms in asthma (text messaging), chronic obstructive pulmonary disease (SMS
program), and heart failure (mobile technology counseling).
There were no statistically significant improvements in chemotherapy symptoms (mobile
app symptom report with recommended self-care advice) (Marcolino et al., 2018). MHealth
interventions resulting in surrogate outcomes showed improved peak flow scores in asthma,
reduced mortality and hospitalizations, improved QOL, improved glycemic control, and improved
BP. SMS reminders improved process of care outcomes as evidenced by attendance rates,
reduced costs, and improved adherence to TB and HIV therapy resulting in decrease viral load.
Secondary outcomes were also improved by mHealth interventions, as evidenced by effective
data collection and reporting, reduction of face to face communication, reduction in
communication delays, improved patient-provider communication, and statistically significant
provider to provider communication. Quality was assessed as high, based on the results
(consistent, generalizable), sample size (sufficient), control (adequate), conclusions (definite),
and recommendations (consistent/based on scientific evidence).
Level III evidence. Alessa, Abdi, Hawley, and de Witt (2018) completed a systematic
review. The purpose of the study was to assess the efficacy of an app to lower BP in individuals
with one or more of the following: HTN, metabolic syndrome risk factors, obstructive sleep
apnea with high cardiovascular risk, and overweight, while also assessing the usability of the
app and patient satisfaction with the use. This systematic review synthesized 21 (nine RCTs, 10
quasi experimental studies and two qualitative studies). While the inclusion of the two qualitative
studies lowered the evidence level to III, those two articles specifically focused solely on the
usability and user satisfaction component of the systematic review. This source of evidence was
included due to the remaining 19 studies focused on the efficacy of the app related to BP to be
of level II evidence (RCTs and quasi-experimental studies). The interventions in this review
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were a mobile phone or tablet app that collected data, provided feedback, connected
with/informed HCP in order to self-manage (measure BP/other biometrics, healthy diet, physical
activity, weight management, medication adherence, and stress management/coping) to HTN.
The app functions were categorized into seven main functions: self-monitor, goal setting,
remind/alert, automatic feedback, education, HCP communication, and stress management.
Duration of the studies ranged from one to 12 months. Study outcomes were BP measurements
and mobile app usability, attitudes, and satisfaction. Alessa et al. (2018) concluded that 67% of
the studies showed a significant association between app use and decreased BP, although
evidence was inconclusive regarding which combination of functionality of the app was most
effective. The app was highly acceptable and easy to use, and participants were satisfied with
use of the app. Quality was assessed as high, based on the results (consistent, generalizable),
sample size (sufficient), control (adequate), conclusions (definite), and recommendations
(consistent/based on scientific evidence).
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Table 2.2
Evidence Table
Citation
(APA)

Purpose

Design

Sample

Measurement/
Outcomes

Alessa, T.,
Abdi, S.,
Hawley,
M.S., de
Witte, L.
(2018).

To assess the
effectiveness
of using apps
to lower blood
pressure, and
to assess
usability and
patients’
satisfaction
with app usage

Systematic
review with
RCTs and
quasi
experimental
studies

21 studies (9
RCTs, 10
quasi
experimental
studies, and 2
qualitative
studies

Effectiveness of apps
in lowering blood
pressure

n = 3112 with
a mean age of
42.4 to 69.5
years having
hypertension,
metabolic
syndrome risk
factors,
obstructive
sleep apnea
with high
cardiovascular
risk, and/or
overweight

Effectiveness of apps
in app usability
Effectiveness of apps
in patients’
satisfaction of use

Results/
Findings
There was a significant
association (p < .05) between
use of apps and decreased
blood pressure in 67% of the
studies.
The app was highly accepted in
all 9 studies.
Participants were satisfied with
the apps, accepted using them
and found them easy to use.

Level/
Quality
Level III

Quality
High
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Jeddi, F.R.,
Nabovati,
E.,
Amirazodi,
S. (2017).

To assess the
features and
effects of
automated ITbased
interventions
on the
outcomes of
selfmanagement
in CKD
patients

Systematic
review of
RCTs

18
8 RCTs
n = 1637
including
Hispanic
transplant
candidates and
their family and
friends,
hemodialysis
patients, adults
with CKD or
diabetes,
including
veterans, with
uncontrolled
blood pressure

Effectiveness of the
IT intervention on
clinical outcomes
(BP, IDWGA, iPTH
and ultrafiltration
rate)
Effectiveness of the
IT intervention on
process of care
outcomes
(medication
adherence, patients’
knowledge,
medication dose,
medication usage,
BP reading, and
dietary sodium
intake)

Self-management outcomes
statistically significant (p <
.0001 to .05) in 80% of the
studies (75% of the clinical
outcomes and 86% of the
process of care outcomes).

Level I
Quality
High
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Kitsiou S.,
Pare, G.,
Jaana, M.,
& Gerber,
B. (2017).

To
systematically
pool evidence
on the
effectiveness
of mHealth
interventions in
patients with
diabetes

Systematic
review of
systematic
reviews
containing
RCTs, nonRCTs, and
cohort
studies

19

15 systematic
reviews (7
RCTs only, 8
with RCTs,
non-RCTs, and
cohort studies
with pre-post
design)
n = 11,833
patients with
diabetes

Effectiveness of
mHealth
interventions (text
messaging of
encouragement,
education, reminders,
and
recommendations,
mobile apps, Bluetooth enabled
glucometers,
websites/portals for
data entry and
patient reports) on
HbA1c

No effect on HgA1c from text
messaging alone [MD -0.15%
(95% CI: -0.77, 0.47)].
Positive, insignificant effect
[0.3% (CI: 0.0, -0.5%)] of
combined SMS with Internet
app for transmission of BG,
reinforcement of diet and
exercise, education, and
medication adjustment.
Text messaging and clinical
feedback have a beneficial
effect on glycemic control [MD
of -0.05% (95% CI: -0.74, 0.26), 3 trials, 280 patients].
Addition of education
component increased effect
size (MD -0.85% vs -0.43).

Level II
Quality
High
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Lee, J.,
Choi, M.,
Lee, S.A.,
& Jiang, N.
(2018).

To examine
the
effectiveness
of mHealth
interventions
on health
outcomes and
process
measures of
chronic
diseases

Systematic
review of
RCTs

20
12 RCTs
n = 3469
including adult
patients with
lung, breast, or
colorectal
cancer on
chemotherapy;
fibromyalgia;
heart failure;
allergic rhinitis
and asthma;
spina bifida;
cardiovascular
disease;
Parkinson’s
disease; and
lung
transplants

Effectiveness of the
mHealth
interventions on
health outcomes
(physiological
=gait/balance,
fatigue,
nausea/vomiting/diarr
hea, sore
mouth/throat, handfoot syndrome, and
pain) and
(psychological =
QOL, depressive
symptoms, anxiety)
and process
measures
(participants’
adherence to,
satisfaction with,
and/or the level of
engagement with
mHealth systems)

Of the articles, 83.3% showed
statistically significant effect (p
= .001 to .05) on health
outcomes by incorporating
mobile apps in managing
chronic dx (improved physical
functioning, adherence to
prescribed meds, and/or ease
of symptom evaluation and
reports to care providers), and
process measures (patient
satisfaction with mHealth
management and ease of use
of smartphone based selfmanagement interventions).

Level I
Quality
High
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Marcolino,
M.S.,
Oliverira,
J.A.Q.,
D’Agostino,
M., Ribiero,
A.L.,
Alkmim,
M.B.M., &
NovilloOrtiz, D.
(2018).

To assess the
effectiveness
of mHealth
interventions
on chronic and
noncommunicable
disease

Systematic
review of
systematic
reviews
containing
RCTs and
non-RCTs

21
23 systematic
reviews
n = 79,665

Primary outcomes: clinical (frequency of
hypoglycemic events,
symptoms, death)
-surrogate (HgA1c,
BP, lipid profile, CVD
risk profile, lung
function, neb use,
weight, BMI,
behavioral or lifestyle
changes)
-process of care
(attendance rates,
medication
compliance, data
management,
communication, time
to dx, time to treat,
professional
workload changes)
Secondary
outcomes: cost,
patient satisfaction
and potential harms
and adverse effects

mHeath interventions improved
symptoms in asthma (text
messaging) [MD 0.36, (95% CI:
-0.56, -0.17)], and HF (mobile
technology counseling) (RR
reduction 20%). No statistically
significant improvement in
COPD (SMS program) or
chemotherapy symptoms
(mobile app symptom report
with recommended self-care
advice).
Improved peak flow scores in
asthma [MD -11.12, CI: 95%, 19.56, -2.68)], reduced
mortality and hospitalizations,
improved QOL, glycemic
control, and BP.
SMS reminders improved
attendance rates, reduced
costs, and improved adherence
to TB and HIV therapy resulting
in decrease viral load.
Effective data collection and
reporting, reduction of face to
face communication, reduction
in communication delays,
improved patient-provider
communication, statistically
significant provider to provider
communication.
*not all statistics given in article

Level II
Quality
High
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Whitehead,
L., &
Seaton, P.
(2016).

To assess the
effectiveness
of mobile
phone and
tablet apps in
selfmanagement
of key
symptoms of
long-term
conditions

Systematic
review
containing
RCTs

22
9 RCTs
n = 2278
patients aged
33.8 to 72.1
years with
diabetes,
chronic lung
disease, and
cardiovascular
disease

Effectiveness of
mobile phone and
tablet app on disease
specific outcomes
(DM, chronic lung
disease, and CVD)

Of the articles, 66.6% of
interventions showed
statistically significant effects
on disease specific outcomes
of interest. 60% app only
interventions statistically
significant in improvement of
symptom management.
*statistics of individual RCTs
not given in article.

Level I
Quality
High
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Construction of Evidence-based Practice
Synthesis of Critically Appraised Literature
Synthesis of the preceding literature identified mHealth interventions to improve
outcomes in chronic disease, which may be translational to a CKD population due to similar
needs of this chronic disease population. Common themes to improve disease-specific
outcomes include communication, reminders, telemonitoring, and education (Alessa et al.,
2018, Jeddi et al., 2017, Kitsiou et al., 2017, Lee et al., 2018, Marcolino et al., 2018, and
Whitehead & Seaton, 2016). Use of these common themes can translate into best practice for
implementation of a mobile app to manage symptoms in patients with CKD.
Communication. In all six appraised sources of evidence, mHealth utilized
communication to improve measured outcomes (Alessa et al., 2018, Jeddi et al., 2017, Kitsiou
et al., 2017, Lee et al., 2018, Marcolino et al., 2018, and Whitehead & Seaton, 2016).
Communication between patient and HCP, as well as communication between HCPs is a
valuable intervention. Communications in the reviewed literature were either sent to the patients
by being generated by a HCP or were sent as a result of the app’s automated responses
(Alessa et al., 2018, Jeddi et al., 2017, Kitsiou et al., 2017, Lee et al., 2018, Marcolino et al.,
2018, and Whitehead & Seaton, 2016).
Reminders. Another function that seems to be a commonality between four of the six
sources of evidence is the use of reminders (Alessa et al., 2018, Jeddi et al., 2017, Kitsiou et
al., 2017, and Marcolino et al., 2018). Reminders addressed appointment times as well as
medication times and disease-specific biometric evaluations, such as BP checks.
Telemonitoring. Telemonitoring or the wearing of a device to record and/or transmit
biometric readings, such as BP, weight, gait, BG, and peak flows, was also demonstrated to
improve disease-specific outcomes in five of six articles (Alessa et al., 2018, Jeddi et al., 2017,
Kitsiou et al., 2017, Lee et al., 2018, and Marcolino et al., 2018).
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Education. Five of six articles demonstrated disease-specific education as an integral
part of a mHealth intervention (Alessa et al., 2018, Jeddi et al., 2017, Kitsiou et al., 2017, Lee et
al., 2018, and Marcolino et al., 2018). Media used for education included SMS, internet, email
and videos.
Best Practice Model Recommendation
After reviewing the appraised literature, the identified best practice to address
implementation of a mobile app to manage symptoms in patients with CKD incorporates
communication, reminders, telemonitoring, and education (see Figure 2.2). By integrating these
components into practice, reduced healthcare utilization and increased patient satisfaction was
expected.

MOBILE APPLICATION IN CKD POPULATION
Figure 2.2
Practice Change
Identify eligible participants from
nephrologist’s daily schedule

Nephrologist to introduce project leader
to participant at completion of his office
visit

Participants given handout of
details of EBP project

After consenting,
participants aided in
downloading CARELogiQ

Participants instructed to
record blood pressures and
weights weekly, record all
appointments in the app, and
complete the Kidney Smart©
education program

Project leader to make weekly calls to
participants to remind them to continue to
record weekly blood pressures and
weights, to enter upcoming clinic
appointments in the app, to adhere to their
medication regimen, and to report any
symptoms in the app

Complete patient satisfaction
survey at conclusion of project

25

MOBILE APPLICATION IN CKD POPULATION

26

CHAPTER 3
IMPLEMENTATION OF PRACTICE CHANGE
The CARELogiQ platform was the cornerstone of this practice change. Eligible
participants downloaded the CARELogiQ app to begin the process of self-management.
Practice change was implemented by utilizing the synthesized best practice interventions
explained above.
Participants and Setting
Participants taking part in this practice change were patients of a local nephrologist, with
CKD, between stages III and V, not on dialysis. The project site was an outpatient nephrology
practice in a Midwest town, consisting of nine nephrologists and seven office locations. Only
patients of the nephrologist who developed the mobile application were included to participate.
Only one of this nephrologist’s two offices was the initial target site of the EBP project. Due to a
low number of participants, a second office site was added.
Complete inclusion criteria for this EBP project required participants:
• 18 years or older
• English speaking
• CKD III to V (including post transplant)
• Consent to participate in the project
• Have a smartphone capable of installing this application
• Agree to download and use the application
• Able to navigate the application
Potential participants were excluded from participating in the project based on the following
criteria:
• Currently receiving dialysis
• Pregnancy

MOBILE APPLICATION IN CKD POPULATION

27

Pre-Intervention Group Characteristics
The targeted nephrology practice was comprised of 264 adult patients, with 180 of these
patients diagnosed with CKD III to IV. Of those 180 patients, 146 had stage III CKD, 27 had
stage IV CKD, two had stage V CKD, and five were stage V post transplantation. Patients with
CKD III made up 55.3% of the total population and 81.11% of the moderate to severe CKD
population, while CKD IV was 10.22% and 15%, CKD V was 0.75% and 1.11%, and CKD V
post transplantation was 1.89% and 2.77%. Eighty-five (47%) of the 180 patients were male,
and 95 (53%) were female. Within this group, race/ethnicity for 37 (21%) were “not available”,
three (2%) were “not available/not Hispanic”, 94 (52%) were “white/not Hispanic”, four (2%)
were “white/Hispanic”, 36 (20%) were “black or African American (AA)/not Hispanic”, one (1%)
was “black or AA/not available”, two (1%) were “Asian/not Hispanic”, and one (1%) was
“other/not Hispanic”. Patients were considered to be part of the practice if they have been seen
in the office within the past year.
This EBP project targeted as many participants as possible from the nephrology group
who met the stated project inclusion criteria. Comparison data consisting of CKD stage, BP,
weight, and hospitalizations and/or ER visits was collected from the previous year’s visits, as
well as the current visit.
Intervention
To prepare for this EBP intervention, a plan was developed to provide step-by-step
guidance for the project leader and the staff at the facility. First, eligible potential participants
were identified from the nephrologist’s daily patient schedule. At the conclusion of the office
visit, the nephrologist introduced the patients to the project leader. After an introduction of the
EBP project, potential participants decided whether to join the project. Once participants
consented to join the project, the project leader gave participants a handout of instructions on
how to download and use the mobile application. Participants had the opportunity to download
the mobile application with the project leader while in the office. Participants also were given
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instructions on recording weekly home BP and weight measurements, as well as instructions for
the educational resource, DaVita’s Kidney Smart© educational website.
Initiation of the intervention began with participants recording weekly home BPs and
weights. Weekly calls to participants were made by the project leader to remind the participants
to continue home BP and weight recordings, to collect a weekly home BP and weight, to
encourage entering upcoming clinic appointments into the mobile application, to encourage
adherence to medications, and to promote the use of the mobile application to report symptoms
as any arose. Participants with abnormal BPs or weights were encouraged to follow up with
their treating provider. The duration of the intervention was planned for 12 weeks. Participants
continued enrollment through October 2019. At the conclusion of intervention, participants were
given a participant satisfaction survey to assess their satisfaction with utilizing the mobile
application.
Comparison
Collection of pre-intervention data was necessary to serve as a comparison to postintervention data in order to analyze the efficacy of the project. Once a participant was initiated
into the project, the project leader reviewed that participant’s chart for healthcare use, consisting
of unscheduled hospitalizations or ER visits for the previous year, as well as for office visits
other than scheduled follow-up appointments within the previous year. The project leader also
reviewed the participant’s chart in order to collect data of the BP readings, last weight, and the
stage of CKD over the past one year of office visits.
Data collection of a non-intervention comparison group was completed. Thirty-two
randomly selected patient charts were reviewed, with 25 stage III CKD, five stage IV CKD, one
stage V CKD, and one stage V CKD post transplantation to create a randomize stratified sample
based on the total number of active patient files in the office. The ages of patients ranged from
43 years to 92 years. Only one had a hospitalization in the past year. Three had ER visits.
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Unplanned office visits were difficult to track, due to no specific documentation signifying the
visit to be unplanned.
Outcomes
Primary and secondary outcomes were employed to evaluate the effectiveness of the
EBP project. The primary outcome of this EBP project was the compared number of
unscheduled hospitalizations or ER visits from the pre-intervention and intervention groups.
Additionally, the total number of encounters post-intervention were compared to the participant’s
pre-intervention visits within the past year, by utilizing a paired t test. The secondary outcome
was participant user satisfaction with the mobile application at the conclusion of the intervention.
Participant user satisfaction was scored utilizing a Likert scale and means were compared. In
addition to collection of the number of unscheduled hospitalizations or ER visits, the number of
contacts with the provider or office through phone calls, mobile app usage for imputing
symptoms, and office visits were also collected. BP and weights were analyzed by trending.
Time
In collaboration with the project site facilitator, the projected timeline of this EBP project
was determined by the literature review, constraints of the project leader’s allowable time, as
well as the project site facilitator request. The duration of intervention in the reviewed literature
most frequently lasted three to six months (Alessa et al., 2018, Jeddi et al., 2017, Kitsiou et al.,
2017, Lee et al., 2018, Marcolino et al., 2018, and Whitehead & Seaton, 2016). Implementation
for this EBP project began September 1st, after IRB approval. The project strived to continue to
invite participants to join until a number of 50 participants was reached, but due to time
constraints, participant invitation closed October 30 th. The project duration was planned to last
four months.
Protection of Human Subjects
The project leader completed an ethics training program as evidenced by a CITI
certificate. Approval for the EBP project was obtained from the Valparaiso University
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Institutional Review Board. Confidential participant information was kept locked at the clinical
site. Participants’ data were de-identified by using codes. A separate master list was used to
assign code numbers based on chart name and date of birth. The master list identifying
participants was kept in a separate file at the project site.
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CHAPTER 4
FINDINGS
This EBP project began by asking the question: how effective is CARELogiQ to selfmanage symptoms compared to non-intervention, in order to reduce healthcare utilization and
to increase patient satisfaction over a 12-week period. The purpose of this EBP project was to
evaluate the efficacy of a CKD mobile application, developed by a local nephrologist, to facilitate
symptom management, while increasing patient satisfaction, and decreasing unplanned
hospitalizations and ER visits. In order to evaluate the effectiveness of this mobile application,
two groups were selected from 180 patients with moderate to severe CKD, a non-intervention
group and an intervention group. Unplanned hospitalizations and ER visits related to CKD
symptoms were assessed within both groups. Unplanned healthcare utilization was compared
within the intervention group pre- and post-intervention, as well as between the non-intervention
and intervention groups. The secondary outcome of patient satisfaction was evaluated by a
“Satisfaction of Care” survey developed by the project manager. Nine out of 10 participants
completed the survey, but not all questions were applicable to all participants. This 12-question
survey was administered by a phone call to participants after completion of the 12-week project.
Other project outcomes were evaluated by analysis of weekly BP and weight recordings.
Utilization of SPSS, version 25.0, facilitated analysis of participant demographic data, as well as
primary and secondary outcome data.
Participants
In this chapter, participant characteristics are detailed and evaluated (see Table 4.1). A
comparison group of 32 non-intervention participants was obtained from a stratified random
sample of the above active patients, ranging in age from 43 to 92 years (M = 71.53, SD = 10.67)
was randomly selected to reflect the total percentages in the moderate to severe CKD office
population. Twenty-five stage III CKD, five stage IV, one stage V, and one stage V with
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transplantation were randomly selected (see Figure 4.1). Of this group, 17 (53%) were male,
and 15 (47%) were female (see Figure 4.2). Race/ethnicity for three (9.4%) was “not available”,
18 (56.3%) were “white/not Hispanic”, 9 (28.1%) were “black or AA/not Hispanic, 1 (3.1%) was
“black or AA/not available”, and one (3.1%) was “other/not Hispanic” (see Figure 4.3).
A total of 10 individuals from the comparison group participated, ranging in age from 43
to 81 years (M = 67.82, SD = 11.99). Nine (90%) participants were in stage III CKD, and one
was (10%) stage IV CKD (see Figure 4.1). Three (30%) participants were male and seven
(70%) were female (see Figure 4.2). For race, six (60%) were “white/not Hispanic”, two (2%)
were “black or AA/not Hispanic”, one was (1%) “Asian/not Hispanic”, and one (1%) was “not
available” (see Figure 4.3).
A chi-square test of independence was calculated comparing the frequency of race
between the non-intervention and intervention groups. A significant difference between the
groups was not found (x2(5) = 4.23, p = .517). Race between the non-intervention group and
intervention group appear to come from similar population proportions.
Testing chi-square of independence for gender between the non-intervention group and
intervention group did not show a significant difference (x2(1) = .92, p = .337). Gender between
the groups appears to have the same population proportion.
Comparing the frequency of stage of CKD, a chi-square test of independence did not
result in a significant difference between the stages (x2(3) = .1.24, p = .745). Non-intervention
and intervention participants were not significantly different based on stage of CKD.
An independent-samples t test comparing the mean ages of the non-intervention and
intervention groups did not find a significant difference between groups (t(41) = .965, p = .34).
The mean of the non-intervention group (M = 71.53, SD = 10.67) was not significantly different
from the mean of the intervention group (M = 67.82, SD = 11.99). Figure 4.4 provides a
visualization of age distribution between the two groups.
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Table 4.1
Participant Characteristics

Characteristics of:

Non-intervention Group (n=32)
n

Stage of CKD
III
IV
V
V with transplant
Gender
Female
Male
Race/Ethnicity
Not Available
White/not Hispanic
Black or African
American/not Hispanic
Black or African
American/Not Available
Other/not Hispanic
Asian/not Hispanic

%

Intervention Group (n=10)
n

%

25
5
1
1

78
16
3
3

9
1

90
10

15
17

47
53

7
3

70
30

3
18

9.4
56.3

1
6

10
60

9

28.1

2

20

1
1

3.1
3.1
1

10
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Figure 4.1
Comparison of Stage of CKD Between Groups

Figure 4.2
Comparison of Gender Between Groups
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Figure 4.3
Comparison of Race Between Groups

Figure 4.4
Comparison of Age Between Groups
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Changes in Outcomes
Statistical Testing and Significance
To determine changes in outcomes, data were analyzed via SPSS, version 25. Primary
and secondary outcomes were analyzed. First, participant healthcare utilization was compared
between the non-intervention group and intervention group utilizing an independent t test.
Second, participant healthcare utilization was compared within the same group, pre-intervention
vs post-intervention, utilizing a paired t test. Description of outcomes, along with tables/figures
detailing data, are explained.
The secondary outcome, satisfaction of care, was evaluated by analyzing the responses
to 12 questions within the “Satisfaction of Care” survey (see Appendix), calculating a mean
score for current use and future use themed questions. Answers in this survey also provide
further insight for use of the mobile app.
Other data were analyzed to determine if this mobile application had an effect on BP and
weight. These biometric markers were collected pre-intervention, and then weekly for twelve
weeks. Line graphs of systolic bp, diastolic bp, and weight were utilized to show a trend over
time during the use of the mobile app. The line graphs also depicted group BPs related to a
target BP for CKD patients.
Findings
In this EBP project, among patients with moderate to severe CKD, this mobile app
(CARELogiQ) was effective to self-manage symptoms in order to reduce healthcare utilization
and increase patient satisfaction with care compared to non-intervention over a four-month
period.
Primary outcome. An independent-samples t test, which compares the means of two
unrelated samples (Cronk, 2018), was planned to assess for changes in the primary outcome.
Out of the 32 participants in the non-intervention group, three had a total of four instances of
healthcare utilization. There were zero instances of healthcare utilization in the intervention
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group. An independent-samples t test comparing the mean healthcare utilization of the nonintervention and intervention groups did not find a significant difference between groups (t(40) =
.930, p = .36). The mean of the non-intervention group (M = 0.125, SD = 0.42) was not
significantly different from the mean of the intervention group (M = 0.00, SD = 0.00). While there
was not a statistical difference, the absolute number of HU was fewer in the intervention group
than the non-intervention group.
A single-sample t test, which compares means within a single sample (Cronk, 2018) was
intended to analyze the interventional group both pre-mobile app use and post-mobile app use.
However, the interventional group did not have healthcare utilization pre- nor post-app use. Due
to the lack of variance in scores within the group, the planned testing could not be utilized
(Cronk, 2018).
Secondary outcomes. Secondary outcome assessment included measurement of
participant satisfaction of care while utilizing CARELogiQ. The satisfaction survey was
developed to evaluate satisfaction with current use of CARELogiQ and to explore features
desired for future use of the app.
Satisfaction with mobile app. The 12-question satisfaction of care survey presented at
the conclusion of the four-month EBP project aided in evaluating what participants thought
about the mobile app (see Table 4.2). Four questions on the survey asked participants about
their reporting of symptoms in the app. Three participants reported symptoms in the mobile app,
with next day or less response time from the physician. One participant did not receive a
response. Of the three participants, satisfaction with physician response time resulted in
participants being “very satisfied” (M = 5, SD = 0, n = 2) with physician response time.
Questions five and six were specific to education and asked if participants were satisfied with
the Kidney Smart© class and if they thought it would be helpful to receive educational
information through the app. Participants more than agreed that the Kidney Smart© class was
satisfactory (M = 4.6, SD = 0.548, n = 5). Participants more than agreed that receiving
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educational information through the app would be helpful (M = 4.33, SD = 0.71, n = 9). Question
seven and eight addressed biometric reporting and asked if participants were satisfied with
weekly BP and weight reports to the project leader and would it be helpful to report weekly BPs
and weights through the app. Participants were more than satisfied with reporting weekly
biometrics to the project leader (M = 4.67, SD = 0.5, n = 9). Participants more than agreed that it
would be helpful to input biometrics into the app (M = 4.67, SD = 0.5, n = 9). Questions nine and
ten addressed targeted reminders. Participants were more than satisfied inputting appointment
times into the app (M = 4.75, SD = 0.46, n = 8). Participants agreed that receiving medication
reminders through the app would be helpful (M = 3.22, SD = 1.79, n = 9). Question 11 evaluated
the overall satisfaction with the mobile app. Participants were somewhat satisfied utilizing
CARELogiQ (M = 3.6, SD = 1.14, n = 9). Suggestions to add to or change in the mobile app
were solicited in question 12. Two common themes emerged; increase functionality of the app
and improve communication through the app.
Current use. Questions five, seven, nine and 11 evaluated current use of the mobile
app regarding education, biometric reporting, reminders, and overall mobile app utilization.
Participants were asked to rate their level of satisfaction utilizing a Likert scale of strongly
disagree (1) to strongly agree (5). Figure 4.5 illustrates the findings. Overall, participants
appeared to be satisfied with current use of the mobile app.
Future use. Questions six, eight, and 10 evaluated future use of the mobile app
regarding education, biometric reporting, and reminders. Participants were asked to rate their
level of satisfaction utilizing a Likert scale of strongly dissatisfied (1) to strongly satisfied (5).
Figure 4.6 illustrates the findings. Participants appeared to be satisfied with the opportunity of a
future use of the app to provide education and the ability to record weekly biometric data. The
mean response to participant satisfaction with future use of reminders was somewhat satisfied.
Blood pressure and weight control. This EBP project also afforded the opportunity to
track weekly BP and weight. According to the NKF (2010), a target BP for CKD patients is
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recommended below 130/80mmHg to slow progression of CKD. A line graph was used to
exemplify BPs over the 12-week intervention period (see Figures 4.7 and 4.8). As
demonstrated, most systolic BP readings were above the recommended 130mmHg line, with
approximately three participant systolic BPs below the recommending reading. Abnormally
elevated BPs were reported to the nephrologist for medical evaluation.
Diastolic BPs demonstrated the majority of readings were below the 80mmHg
recommended threshold; however, three participants were consistently above this threshold.
Weekly weights were the most consistent of the readings (see Figure 4.9). As seen in
the figure, three participants are at or above 250 pounds. It is reasonable to suggest that these
participants are obese. The majority (70%) of participants fall below 200 pounds. Height and
BMI were not collected, so this graph does not evaluate obesity, but illustrates the consistency
of weights. Rapid weight changes in CKD can signify a problem with fluid balance and edema
(NKF, 2010). None of the participants required treatment due to rapid weight gain or loss.
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Table 4.2
Satisfaction Survey for the Mobile App Usage

Question

M

SD

4.6

0.55

4.67

0.5

4.75

0.46

3.6

1.14

4.33

0.71

4.67

0.5

3.22

1.79

Current Usage
5. How satisfied were you with the
Kidney Smart© education class? (n = 5)
7. How satisfied were your with reporting your blood
pressure and weight to the project leader every week? (n = 9)
9. How satisfied were you with adding your upcoming
appointments to the mobile application for appointment
reminders? (n = 8)
11. Overall, how satisfied were you with the mobile
application? (n = 5)
Future Usage
6. It would be helpful to receive educational information
through the app. (n = 9)
8. It would be helpful to be able to add your blood pressure
and weight into the app on a weekly basis. (n = 9)
10. It would be helpful to receive medication reminders
through the app. (n = 9)
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Figure 4.5
Satisfaction of Current App Use

Figure 4.6
Agreement of Future App Use
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Figure 4.7
Intervention Group Systolic BP Trend

Figure 4.8
Intervention Group Diastolic BP Trend
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Figure 4.9
Intervention Group Weight Trend
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CHAPTER 5
DISCUSSION
This EBP project set out to evaluate the effectiveness of a mobile app to facilitate
symptom management in order to increase patient satisfaction and decrease healthcare
utilization. In this chapter, the data from Chapter 4 will be interpreted, along with an evaluation
of the EBP framework, strengths and weaknesses of the EBP project, and implications for future
use related to clinical practice, theory, research, and education.
Explanation of Findings
The primary outcome evaluated in this EBP project was measuring healthcare utilization
after use of CARELogiQ. As seen in the preceding literature (Alessa et al., 2018, Jeddi et al.,
2017, Kitsiou et al., 2017, Lee et al., 2018, Marcolino et al., 2018, and Whitehead & Seaton,
2016), common themes of communication, reminders, telemonitoring, and education were
utilized to improve symptom management, resulting in decreased healthcare utilization. While
not statistically significant, the decrease in healthcare utilization in the intervention group is of
clinical significance. The secondary outcome evaluated participant satisfaction using
CARELogiQ. Consistent with Alessa et al. (2018) and Lee et al. (2018), participants were
satisfied using CARELogiQ in this EBP project.
Applicability of the EBP Framework
The step-by-step approach of the Stetler model facilitated the implementation of this
project (Stetler, 2001). The initial step of the model, preparation, began by guiding the
identification of a problem requiring change. The development of a mobile app, and subsequent
request to launch, spurred the review of the literature. It was then established that high
healthcare costs, negative health outcomes, and poor quality of life from CKD (Donald et al.,
2018) led to the question whether employment of a mobile app to manage symptoms could
decrease unscheduled healthcare utilization. A PICOT question was developed, and a search
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strategy was prepared seeking the highest levels of evidence to support this project. The
validation phase of the model guided the evaluation and appraisal of the evidence, resulting in a
determination of fit for use and leading to the comparative evaluation/decision-making phase.
Synthesis of the evidence and evaluation of commonalities were completed, generating best
practice recommendations. A decision was made to employ the recommendations to change
practice by utilizing the mobile app to aid participants in self-management of CKD. The
translation/application phase was fulfilled by formulating a detailed plan of change and acting
upon that plan in the practice setting. Lastly, the evaluation phase was comprised of evaluating
the outcome data to determine if the practice change led to meeting the outcome goals of
increased patient satisfaction and reduced healthcare utilization.
The Stetler model allowed for an ease-of-use implementation of this project by utilizing a
step-by-step approach. The Stetler model was advantageous as a framework due to possessing
the flexibility to integrate research into practice on both a formal and informal level, as well as
individually or organizationally (Stetler, 2001). The highest evidence was formally integrated in
this project as evidenced by a formal change in office procedure for project participants. Due to
the project leader implementing the majority of the project, this practice change was more
individually applied.
The first phase of the model allowed for consideration of external factors to influence
identification of EBP activities (Stetler, 2001). The developer of CARELogiQ was a major
influence in pursuing this EBP project. Another strength of this model was the ability to accept or
reject evidence based on clinical significance, rather than the strength of the evidence (Phase 2)
(Stetler, 2001). Due to inclusion of qualitative studies, one systematic review discussed in
Chapter 2 was not as strong as other evidence utilized in this project, but the clinical
significance of the evidence contributed to the overall support of this project. In addition, some
evidence was not specific to CKD, but to chronic disease. This evidence was determined to be
vital to this project, and included based on “fit of setting”, or the similarity of the sample and
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study environment to the project population and setting (Stetler, 2001). In the decision-making
phase (Phase IV), decisions on what evidence to use or how to utilize evidence are practitionerlevel decisions (Stetler, 2001). The project leader extrapolated the components of best practice
from the literature and developed individual vehicles to employ components to complement the
current functionality of the app. Education was delivered via the Kidney Smart© classes,
reminders were delivered via weekly phone calls, and telemonitoring was obtained through
weekly phone calls. The fourth phase of the model allows for consideration of need for
appropriate, reasoned variation (Stetler, 2001). This allowed for changes to the inclusion
criteria, including the change from smartphone to smart device and opening participation to
patients in a second practice location. In the final phase, Stetler (2001) allows for a “consider
use” option. While the outcome of this project did not yield statistically significant results,
stakeholders can “consider use” by making alterations to the project based on project findings
and recommendations, and implement a pilot project.
A limitation of the Stetler model was the dependence on the competency, knowledge,
and skill level of the project leader. Without these characteristics, research application is
vulnerable to not being appropriate, effective or evidence-based (Stetler, 1994). While the
comprehensive step-by-step approach is a strength of the model, the project leader found the
complexity of details in each step overwhelming and a weakness due to the amount of time
spent attempting to comprehend the intricacies of these details.
Strengths and Limitations of the DNP Project
Strengths and weaknesses were identified upon evaluation of this EBP project. While
high level, high quality evidence directed the implementation of this project, due to functionality
not yet employed by the app, some limitations were identified. A more detailed discussion of
strengths and weakness is continued below.
Strengths
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Strengths of this project included strong evidence to support the practice change. The
higher the level and quality of the evidence, the stronger the recommendation represents best
practice (Dang & Dearholt, 2017). Most of the literature reviewed was level I (Jeddi et al., 2017,
Lee et al., 2018, and Whitehead & Seaton, 2016) and level II (Kitsiou et al., 2017, and Marcolino
et al., 2018), with one level III piece of evidence (Alessa et al., 2018) that was deemed of high
clinical significance. All evidence was of high quality (Alessa et al., 2018, Jeddi et al., 2017,
Kitsiou et al., 2017, Lee et al., 2018, Marcolino et al., 2018, and Whitehead & Seaton, 2016).
These characteristics led to concrete recommendations to guide the practice change. The EBP
model, Stetler, was another strength of this EBP project. The step-by-step approach of this
model provided a concrete framework to develop this project. It was also advantageous to have
an invested project facilitator who was supportive of a successful EBP project implementation.
The site facilitator, the nephrologist who developed the CARELogiQ app, championed its use in
this EBP project. Having access to the mobile app creator allowed for ease of access to
answers regarding the functions of the mobile app. The practice of this nephrologist provided a
setting conducive to a successful project. The office staff was invaluable for accessing patient
information in the EMR system.
Best practice recommendations derived from the literature included communication
(Alessa et al., 2018, Jeddi et al., 2017, Kitsiou et al., 2017, Lee et al., 2018, Marcolino et al.,
2018, and Whitehead & Seaton, 2016), reminders (Alessa et al., 2018, Jeddi et al., 2017,
Kitsiou et al., 2017, and Marcolino et al., 2018), telemonitoring (Alessa et al., 2018, Jeddi et al.,
2017, Kitsiou et al., 2017, Lee et al., 2018, and Marcolino et al., 2018), and education (Alessa et
al., 2018, Jeddi et al., 2017, Kitsiou et al., 2017, Lee et al., 2018, and Marcolino et al., 2018)
with an app. CARELogiQ provided a platform for participants to report symptoms through the
app, without needing to contact the office. This process of reporting symptoms allowed for direct
communication with the nephrologist, compared to current office procedure of office staff writing
down a patient message and attaching it to a clipboard to be reviewed at the end of the day.
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The communication feature also gave participants more control over how symptoms were
reported to the nephrologist, by having participants answer questions of duration and severity
within the report. There was no need to rely on office staff to transcribe and report an accurate
message from the participant.
While telemonitoring relied on weekly, manual checks of BP and weights, the collection
of these recordings benefitted participants. Several participants were identified by the project
leader as having abnormal BP readings that required medication adjustments. These checks
resulted in participants having closer attention given to the management of their BP between
office visits. This project also identified a trend in the majority of participants’ systolic BPs being
above the recommended value for CKD. The telemonitoring component of best practice can be
enhanced with the addition of a device to link to CARELogiQ to directly record and transmit BPs
and weights, allowing for tighter control of these biometric markers.
While the education component of best practice recommendations was not yet
functionable through the CARELogiQ app, the Kidney Smart © education class provided another
strength to this project. Participants signed up for a 90-minute, group structured class at an
outside facility, conducted by an outside educator. Participants who attended this class were
highly satisfied with the information they obtained and benefitted from increased knowledge of
their disease. Most participants stated they would like an education component within
CARELogiQ. Incorporation of an educational section in CARELogiQ could potentially provide
the same level of satisfaction or greater, which may result in better self-management of their
CKD.
This EBP project also identified another patient care issue that could be improved. As
stated previously, of the 180 patients in this setting with moderate to severe CKD, 37 (21%) did
not have their race identified. Due to African Americans having higher average muscle mass
and creatinine generation rate, the GFR of African Americans is higher than non-African
American patients (NKF, 2014). Reports of GFR not adjusted for African American patients
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would not accurately reflect the severity of CKD in the African American patient. It is important
to collect complete demographics, including race, to accurately interpret lab results of patients.
Limitations
CARELogiQ was still in development, resulting in all functionality not being available as
had been projected. Best practice recommendations for this EBP project included use of
automatic reminders; however, CARELogiQ only allowed for the manual input of upcoming
appointment dates. It would be beneficial for patients to have upcoming appointments
automatically populate in the app for accuracy and completeness. Other reminders that would
have been appropriate to incorporate from the best practice recommendations included
medication reminders and biometric evaluation reminders. For this project, the project leader
augmented this concept by reminding participants to enter upcoming appointments in the app,
to take their medication as scheduled, and to log their BP and weights at least weekly for
collection of these data in the weekly project leader phone call to participants. Incorporation of
these features into the CARELogiQ app platform would be potentially beneficial.
Another limitation of this project was the low number of participants. While the nonintervention group was based on the number of total patients in the clinic, the intervention group
was not limited beyond the inclusion/exclusion criteria. Many patients either did not have access
to a smartphone or tablet, felt uncomfortable using mobile apps, or were not interested in
participating in the project. When no access to a smartphone was identified as a common
limitation to enrolling participants, opening up the inclusion criteria to include smart devices,
such as a tablet was beneficial. Future EBP projects may benefit from office supplied devices
obtained by funds from a grant. Participants who were uncomfortable with using mobile apps
were given the opportunity to download CARELogiQ in the office with assistance from the
project leader, although some potential participants still declined the invitation due to this issue.
The project leader met patients on the same day that the invitation was extended to participate
in the project. Patients who stated they just were not interested in participation may have been
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more willing to participate if the project was introduced to them by staff with whom they already
had a clinic relationship.
The timeframe of the project was also a limitation. Initially, only one practice location
schedule was utilized to invite participants. In an effort to increase the number of potential
participants, a second practice location’s schedule was added. This site added another half-day
clinic per week. In total, the nephrologist was scheduled three half-days per week. The limited
number of office hours, along with the four-month duration of the project may have limited the
source of potential participants. Evidence used in this project had durations of a few minutes to
24 months, with most studies identifying durations lasting up to 12 months (Alessa et al., 2018,
Jeddi et al., 2017, Kitsiou et al., 2017, Lee et al., 2018, Marcolino et al., 2018, and Whitehead &
Seaton, 2016). Having more scheduled clinics per week to invite participants would potentially
have resulted in a larger number of participants in the intervention group.
Overall, the lack of functionality of the mobile app resulted in limitations of the project.
While the mobile app allowed participants to report their symptoms to their provider through the
mobile app, two-way messaging through the mobile app was not possible. Participants were
able to manually input upcoming appointments into the mobile app, but appointments did not
automatically populate in the mobile app at the time an appointment was scheduled.
Participants were also frustrated by difficulty signing up for the initial app usage. Some
participants were able to sign up, but then unable to sign in to the app after previously being
able to do so. To overcome the limitations of the mobile app, the project leader called
participants weekly by phone to collect BP and weight readings. It was not possible to collect
these data by text messaging, through the mobile app, or by a direct telemonitoring device
connected to the smartphone or tablet. The mobile app also lacked the ability to store these
biometric readings. Lastly, the mobile app did not provide a platform for participants to receive
any direct educational information, either through links to outside sources, or educational
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references within the mobile app. The addition of these features would be an added benefit to
patients to review educational materials at any time.
Implications for the Future
Practice
Utilizing CARELogiQ to self-manage symptoms may be effective to reduce healthcare
utilization and increase patient satisfaction of care. Providers can use CARELogiQ to empower
patients to be more self-sufficient. Patients would have more control over management of their
CKD. By reporting symptoms directly into the app, providers would be able to receive
information in real time, allowing for the provider to determine the level of urgency requiring a
response. Internalizing telemonitoring functionality could provide greater control over BP and
weight between office visits. Storing biometric data in the app could allow for easy review of
biometric trends during office appointments. The data gathered in this project have
demonstrated a trend of systolic BPs higher than the recommended value. Providers could use
this app to aid in the normalization of BPs. Appointment reminders could reduce the amount of
missed appointments, and reminders for medication and biometric evaluations could improve
care as well by serving as a reminder to take scheduled medications and check BPs and
weights. The education component of the app could compliment and reinforce the educational
information the provider is giving to the patient during office visits. The app could provide “tabs”
for education within the app, links to other sources of education outside the app, and provide
resources for additional education such as Kidney Smart©. With increased functionality,
CARELogiQ has the potential to aid providers in the management of CKD. It may also be
beneficial to have advanced practice registered nurses as dedicated CARELogiQ navigators,
managing patient care through the CARELogiQ app within the institution implemented.
Model/Framework/Theory
The Stetler model provided a concrete framework for this EBP project. This model
provided a step-by-step approach to guide this project through the five phases, with the ability to
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loop back to previous phases as needed to allow for variations. Projects that are implemented
mainly by an individual project leader are well-suited for this model. This model also encourages
clinically significant evidence to be considered in addition to evidence graded as strong. Future
EBP projects would benefit from using the Stetler model as an EBP framework for similar
projects due to the guidance through each step from identification of a problem, review of the
literature, synthesis of the evidence, implementing the plan, and evaluation of the project.
Further guidance could be attained by the addition of a theoretical framework. Although this
EBP project did not utilize a theoretical framework, several theories may be of assistance in
future EBP projects.
Research
While the findings of the primary outcome of this project were not statistically significant,
this EBP project can contribute to future research and future EBP projects. This EBP project is
the first to evaluate use of CARELogiQ. Strengths and limitations of the project can be utilized to
make changes to the app functionality and design of a future EBP project. A pilot project could
also be implemented based of the results of this EBP project, potentially leading to statistically
significant findings, allowing for commercial use of CARELogiQ.
Education
This EBP project highlighted some important areas of needed education. Staff should be
educated on the need to identify race in all demographic data collected on patients. Access to
this demographic data is imperative to accurately diagnose the stage of CKD for individual
patients and monitor their clinical progress.
For patients, the education component that could be built into CARELogiQ would be
beneficial by having information about their disease at their fingertips. The mobile app could
also provide a resource link for additional education opportunities. Attendance of Kidney
Smart© classes should continue to be strongly encouraged.
Conclusion
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The purpose of this project was to initiate the use of CARELogiQ in an outpatient CKD
clinic to positively affect CKD self-management resulting in increased patient satisfaction of care
and decreased hospitalizations and ER visits. While healthcare utilization did decrease in the
intervention group, this was not statistically significant. Having a larger intervention sample size,
in addition to a longer duration of time to invite participants, may have contributed to significant
outcomes.
In response to the secondary outcome, patients were satisfied using CARELogiQ,
although attenuated by lack of some available functions and trouble with logging into the app.
With further development of CARELogiQ, patient satisfaction could only be improved with
increased functionality of the mobile app. Future CARELogiQ EBP projects may lead to
significant outcomes with a larger sample size, a longer implementation time, added
functionality of CARELogiQ, and a smart device provided to participants who did not have their
own device. By improving symptom management, CARELogiQ could reduce HU, leading to a
positive impact on CKD burden.
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ACRONYM LIST
BG: Blood Glucose
BP: Blood Pressure
CINAHL: Cumulative Index of Nursing and Allied Health
CKD: Chronic Kidney Disease
CVD: Cardiovascular Disease
DM: Diabetes
GFR: Glomerular Filtration Rate
HCP: Health Care Provider
HF: Heart Failure
HTN: Hypertension
JBI: Johana Briggs Institute
JHNEBP: Johns Hopkins Nursing Evidence-Based Practice Research Evidence Appraisal Tool
KDIGO: Kidney Disease Improving Global Outcomes Initiative
KDOQI: Kidney Disease Outcomes Quality
mHealth: Mobile Technology
NKF: National Kidney Foundation
PDA: Personal Digital Assistant Devices (PDAs)
SMS: Short Message Service
US: United States
USRDS: United States Renal Data System
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APPENDIX
Satisfaction of Care Survey
SATISFACTION OF CARE SURVEY
Thank you for your time and effort to participate in our project. Please answer the questions
below as best you can. The information will be helpful for future developments of the app. If the
question does not apply to you, just answer “NA”. Your answers will be anonymous.
1. Approximately, how many times did you report symptoms in the mobile application?
2. What symptom(s) did you report?
3. How long did it take to get a call back for your reported symptom(s)?
4. The length of time it took for a response to your reported symptoms was satisfactory. SD,
D, N, A, SA or NA
5. The Kidney Smart© education class was satisfactory. SD, D, N, A, SA or NA
6. It would be helpful to receive educational information through the app. SD, D, N, A, SA
7. How satisfied were you with reporting your blood pressure and weight to the project
leader every week? SD, D, N, S, VS
8. It would be helpful to be able to add your blood pressure and weight into the app on a
weekly basis. SD, D, N, A, SA
9. How satisfied were you with adding your upcoming appointments to the mobile
application for appointment reminders? VD, D, N, S, VS
10. It would be helpful to receive medication reminders through the app. SD, D, N, A, SA
11. Overall, how satisfied were you with the mobile application. VD, D, N, S, VS
12. Do you have any suggestions to add to or change in the mobile application?

